While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therapy in ...
MSD and Eisai’s combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) has shown a durable benefit of five years in a Phase III trial. In KEYNOTE-775/ Study 309 (NCT03517449), MSD’s ...
Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...
KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch ...
Adding Keytruda to chemotherapy improved survival outcomes in patients with endometrial cancer, regardless of their mismatch repair or PD-L1 status. Keytruda (pembrolizumab) plus chemotherapy improved ...
A statistically significant improvement in progression free survival was observed with pembrolizumab plus chemotherapy in both the dMMR and pMMR populations. The Food and Drug Administration (FDA) has ...
Add Yahoo as a preferred source to see more of our stories on Google. The trial has shown curability of the combination over a five-year period. Image credit: Nemes Laszlo / Shutterstock.com MSD and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results